Interim analysis from a phase 2 randomized trial of EuCorVac-19: a recombinant protein SARS-CoV-2 RBD nanoliposome vaccine

Overview of attention for article published in BMC Medicine, November 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 23 news outlets

twitter: 6 X users

Citations

dimensions_citation: 15 Dimensions

Readers on

mendeley: 33 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 23 news stories from 23 outlets.

POP Biotechnologies' SNAP Vaccine System Safe and Effective in a Phase II Clinical Trial for COVID-19

MarketScreener, 01 Dec 2022

POP Biotechnologies (POP BIO), a Buffalo, New York-based biopharmaceutical startup, announces the publication of an interim…

POP Biotechnologies' SNAP Vaccine System Safe and Effective in a Phase II Clinical Trial for COVID-19

ABC27, 30 Nov 2022

BUFFALO, N.Y., Nov. 30, 2022 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a Buffalo, New York-based biopharmaceutical…

News story from News Channel 8 on Wednesday 30 November 2022

News Channel 8 , 30 Nov 2022

POP Biotechnologies' SNAP Vaccine System Safe and Effective in a Phase II Clinical Trial for COVID-19

KOIN 6, 30 Nov 2022

BUFFALO, N.Y., Nov. 30, 2022 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a Buffalo, New York-based biopharmaceutical…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 19 additional news stories.